MX382054B - Composición farmacéutica que comprende derivado de quinolina o sal del mismo. - Google Patents
Composición farmacéutica que comprende derivado de quinolina o sal del mismo.Info
- Publication number
- MX382054B MX382054B MX2018008549A MX2018008549A MX382054B MX 382054 B MX382054 B MX 382054B MX 2018008549 A MX2018008549 A MX 2018008549A MX 2018008549 A MX2018008549 A MX 2018008549A MX 382054 B MX382054 B MX 382054B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- salt
- quinoline derivative
- pharmaceutically acceptable
- provides
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona una composición farmacéutica que comprende un derivado de quinolina o una sal del mismo. Específicamente, la invención proporciona una composición farmacéutica que comprende un (R, E)-N-(4-(3-cloro-4-(piridina-2-ilmetoxi)fenilamino) -3-ciano-7-etoxiquinolina-6-ilo)-3-(1-metilpirrolidina-2-il)-propeneamida o una sal farmacéuticamente aceptable de la misma, una polivinilpirrolidona reticulada y al menos un excipiente farmacéuticamente aceptable. La composición farmacéutica tiene una propiedad de disolución rápida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610056739 | 2016-01-27 | ||
| PCT/CN2017/072155 WO2017129087A1 (zh) | 2016-01-27 | 2017-01-23 | 一种含有喹啉衍生物或其盐的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018008549A MX2018008549A (es) | 2018-09-19 |
| MX382054B true MX382054B (es) | 2025-03-13 |
Family
ID=59397432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008549A MX382054B (es) | 2016-01-27 | 2017-01-23 | Composición farmacéutica que comprende derivado de quinolina o sal del mismo. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11065241B2 (es) |
| EP (1) | EP3378478B1 (es) |
| JP (1) | JP6864691B2 (es) |
| KR (1) | KR102720987B1 (es) |
| CN (2) | CN108354909B (es) |
| AU (1) | AU2017212452B2 (es) |
| BR (1) | BR112018014559A2 (es) |
| CA (1) | CA3011525C (es) |
| HK (1) | HK1243358B (es) |
| MX (1) | MX382054B (es) |
| RU (1) | RU2743014C2 (es) |
| TW (1) | TWI726978B (es) |
| WO (1) | WO2017129087A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3701948A4 (en) * | 2017-10-24 | 2021-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH QUINOLINE DERIVATIVE |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101824029A (zh) * | 2009-03-05 | 2010-09-08 | 厦门艾德生物医药科技有限公司 | 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途 |
| CN102020639A (zh) * | 2009-09-14 | 2011-04-20 | 上海恒瑞医药有限公司 | 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用 |
| CN102675287A (zh) * | 2011-03-11 | 2012-09-19 | 江苏恒瑞医药股份有限公司 | (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用 |
| CN103987700B (zh) * | 2012-03-09 | 2016-08-31 | 江苏豪森药业集团有限公司 | 4-喹唑啉胺类衍生物及其用途 |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| CN103539783A (zh) * | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
-
2017
- 2017-01-23 WO PCT/CN2017/072155 patent/WO2017129087A1/zh not_active Ceased
- 2017-01-23 BR BR112018014559-9A patent/BR112018014559A2/pt active IP Right Grant
- 2017-01-23 HK HK18103054.7A patent/HK1243358B/zh unknown
- 2017-01-23 CA CA3011525A patent/CA3011525C/en active Active
- 2017-01-23 JP JP2018533610A patent/JP6864691B2/ja active Active
- 2017-01-23 EP EP17743702.7A patent/EP3378478B1/en active Active
- 2017-01-23 MX MX2018008549A patent/MX382054B/es unknown
- 2017-01-23 US US16/071,157 patent/US11065241B2/en active Active
- 2017-01-23 CN CN201810446955.8A patent/CN108354909B/zh active Active
- 2017-01-23 CN CN201780000923.9A patent/CN107405344B/zh active Active
- 2017-01-23 KR KR1020187022625A patent/KR102720987B1/ko active Active
- 2017-01-23 TW TW106102382A patent/TWI726978B/zh active
- 2017-01-23 AU AU2017212452A patent/AU2017212452B2/en active Active
- 2017-01-23 RU RU2018128411A patent/RU2743014C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3378478A1 (en) | 2018-09-26 |
| TW201726135A (zh) | 2017-08-01 |
| KR102720987B1 (ko) | 2024-10-24 |
| TWI726978B (zh) | 2021-05-11 |
| KR20180103089A (ko) | 2018-09-18 |
| AU2017212452A1 (en) | 2018-08-02 |
| MX2018008549A (es) | 2018-09-19 |
| AU2017212452B2 (en) | 2022-04-14 |
| US11065241B2 (en) | 2021-07-20 |
| CA3011525C (en) | 2023-12-05 |
| EP3378478B1 (en) | 2022-05-11 |
| CN107405344B (zh) | 2018-08-14 |
| RU2018128411A (ru) | 2020-02-27 |
| EP3378478A4 (en) | 2018-12-26 |
| WO2017129087A1 (zh) | 2017-08-03 |
| CA3011525A1 (en) | 2017-08-03 |
| RU2743014C2 (ru) | 2021-02-12 |
| JP6864691B2 (ja) | 2021-04-28 |
| RU2018128411A3 (es) | 2020-04-30 |
| US20200138803A1 (en) | 2020-05-07 |
| HK1243358B (zh) | 2019-08-16 |
| CN108354909B (zh) | 2021-05-14 |
| CN107405344A (zh) | 2017-11-28 |
| BR112018014559A2 (pt) | 2018-12-11 |
| CN108354909A (zh) | 2018-08-03 |
| JP2019503366A (ja) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| SA520411990B1 (ar) | مركبات مفيدة لتثبيط إنزيم كيناز 7 المعتمد على السيكلين | |
| MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
| SA519401336B1 (ar) | تركيبة صيدلية | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
| EP3181559A4 (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
| HUE063879T2 (hu) | 4-(l,3,4-oxadiazol-2-il)piridin-2(lH)-on származékok mint hiszton-deacetiláz 6 (HDAC6) inhibitorok például a fertõzések kezelésében | |
| MX2017006447A (es) | Agentes antifungicos. | |
| ZA202004548B (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| TN2016000489A1 (en) | Carboxamide derivatives. | |
| MX384034B (es) | Agente terapeutico para cancer de mama. | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| SG11202101451QA (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| TN2016000491A1 (en) | Carboxamide derivatives. | |
| PH12017500436A1 (en) | Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| BR112018014559A2 (pt) | composição farmacêutica compreendendo um derivado de quinolina ou sal da mesma | |
| MX380123B (es) | Metodo para preparar una composicion farmaceutica que comprende un derivado de quinolina o una sal del mismo. | |
| AR111255A1 (es) | Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio | |
| EA201991007A1 (ru) | Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения | |
| EA201990506A1 (ru) | Фармацевтическая композиция | |
| WO2019209208A3 (en) | Controlled-release pharmaceutical compositions of ivabradine |